Short answer
PUMA BIOTECHNOLOGY, INC. (PBYI) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $45M (down 2.6% year over year) with net income of −$4M.
Q1 2026 key financials · XBRL
- Revenue
- $45M
- −2.6% YoY
- Net income
- −$4M
- −226.2% YoY
- Operating margin
- -8.5%
- EPS (diluted)
- −$0.07
- −216.7% YoY
Source: XBRL data from the PUMA BIOTECHNOLOGY, INC. (PBYI) Q1 2026 10-Q on SEC EDGAR. USD.
PUMA BIOTECHNOLOGY, INC. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Risk factors section not provided; no quarter-specific changes identifiable
- Financing documentation update: Ninth Note Purchase Agreement amendment dated April 16, 2026
- Equity dilution risk: no unregistered equity sales or issuer repurchases during quarter
- Insider-trading compliance risk: no director or officer trading-plan changes during quarter
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other PUMA BIOTECHNOLOGY, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.